市場調查報告書

子宮內膜癌症的全球市場:成長,趨勢,及預測(2019年∼2024年)

Endometrial Cancer Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391491
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
子宮內膜癌症的全球市場:成長,趨勢,及預測(2019年∼2024年) Endometrial Cancer Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 112 Pages
簡介

全球子宮內膜癌症市場在2019年∼2024年間,預測將以4.5%的年複合成長率成長。

本報告提供全球子宮內膜癌症市場的相關調查,市場機會和趨勢,成長及阻礙因素,癌症的類型、療法類型、診斷方法、各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭情形

第5章 市場區隔

  • 癌症的各類型
    • 子宮內膜癌症
    • 子宮肉瘤
  • 各療法類型
    • 免疫療法
    • 放射線治療
    • 化療
    • 其他
  • 各診斷方法
    • 切片檢查
    • 骨盆超音波
    • 子宮鏡檢查
    • 電腦斷層掃描
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Sun Pharmaceuticals
    • Mylan
    • AstraZeneca Plc
    • Novartis AG
    • Bristol-Myers Squibb Company
    • R-Pharm-US LLC.
    • Pfizer Inc.
    • Elekta AB
    • Varian Medical Systems, Inc.

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55034

Market Overview

The global endometrial cancer market is expected to register a CAGR of 4.5% over the forecast period. Factors responsible for the growth of this market include a rise in awareness about uterine diseases and their available therapies, innovation in drug development and subsequent technological advancements, and increasing healthcare expenditure. For instance, in most countries, the rate at which healthcare expenditure is increasing is higher than the rate of economic growth, and this is a trend that has been observed over the decades. The presence of equitable, responsive, and efficient health systems across the countries of North America, Europe, and Asia-Pacific has also contributed to the maximum share of GDP being utilized as healthcare expenditure. Moreover, with the increase in the number of people diagnosed with cancer, the introduction of new therapies is expected to increase the costs of cancer care. Cancer treatment can be very expensive, especially with the patients and survivors often needing long-term treatment and monitoring. Additionally, attractive healthcare insurance plans and better reimbursement rates play a vital role in increasing people's expenditure on treatments, which is expected to drive the market studied.

However, factors, such as the adverse effects of the treatment and high toxicity of drugs are expected to hinder the market growth.

Scope of the Report

Endometrial cancer is the malignancy that develops in the layers of the cells that form the endometrium, the lining of the uterus. Women with high blood pressure, diabetes, or breast cancer are at a greater risk of being affected by endometrial cancer.

Key Market Trends

Chemotherapy is expected to hold the Highest Revenue Share in the Type of Therapy Segmentation

In the global endometrial cancer market, the chemotherapy segment is expected to witness a moderate CAGR, owing to the lesser number of drugs approved for the treatment of endometrial cancer. However, the segment is expected to hold the largest share in the type of therapy; this is due to the high adoption rate of chemotherapy when compared to radiation and surgical treatment. Besides, the chemotherapeutic agents, such as carboplatin and paclitaxel, are commonly recommended as the first line of therapy in the majority of the cancer cases, which increases demand for these products. For example, recently the US FDA approved the IXEMPRA (ixabepilone) for use in the treatment of endometrial cancer and this is expected to drive the growth of the market.

North America dominates the Market and expected to do Same in the Forecast Period

North America currently dominates the market for endometrial cancer and is expected to continue its stronghold for a few more years due to a high incidence of uterine serous carcinoma. In North America, the United States holds the largest market share. This can be majorly attributed to increasing prevalence rates of endometrial cancers. For instance, according to the American Cancer Society, it is estimated that in 2019, approximately 61,880 new cases of cancer of the uterus will be diagnosed in the United States. This, along with other factors, such as the rising awareness for the diagnosis of cancer and the presence of the developed healthcare infrastructure are expected to propel the market in the United States.

Competitive Landscape

The endometrial cancer market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. Due to the rising prevalence of cancer, there are several products in the trails; henceforth, it is expected that few other smaller players may enter into the market. Some of the major players of the market are Bristol-Myers Squibb Company, Pfizer Inc., R-Pharm-US LLC, Elekta AB, and Varian Medical Systems, Inc., among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Awareness about Uterine Diseases and their Available Therapies
    • 4.2.2 Increasing Healthcare Expenditure
    • 4.2.3 Innovation in Drug Development and Subsequent Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated with the Treatment
    • 4.3.2 Adverse Effects of the Treatment and High Toxicity of Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Cancer
    • 5.1.1 Endometrial Carcinoma
      • 5.1.1.1 Adenocarcinoma
      • 5.1.1.2 Carcinosarcoma
      • 5.1.1.3 Squamous Cell Carcinoma
      • 5.1.1.4 Other Types of Cancer
    • 5.1.2 Uterine Sarcomas
  • 5.2 By Type of Therapy
    • 5.2.1 Immunotherapy
    • 5.2.2 Radiation Therapy
    • 5.2.3 Chemotherapy
    • 5.2.4 Other Types of Therapies
  • 5.3 By Diagnosis Method
    • 5.3.1 Biopsy
    • 5.3.2 Pelvic Ultrasound
    • 5.3.3 Hysteroscopy
    • 5.3.4 CT Scan
    • 5.3.5 Other Diagnosis Methods
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Sun Pharmaceuticals
    • 6.1.2 Mylan
    • 6.1.3 AstraZeneca Plc
    • 6.1.4 Novartis AG
    • 6.1.5 Bristol-Myers Squibb Company
    • 6.1.6 R-Pharm-US LLC.
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Elekta AB
    • 6.1.9 Varian Medical Systems, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS